Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Elotuzumab

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    BMS' Biologic Emplicti (Elotuzumab) Receives Approval in the U.S.
    BMS' Biologic Emplicti (Elotuzumab) Receives Approval in the U.S.

    22 Mar 2022

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761035

    FDA
    22 Mar 2022
    Share Share
    Indapta Therapeutics Announces New Preclinical Data for Proprietary G-NK Cells
    Indapta Therapeutics Announces New Preclinical Data for Proprietary G-NK Cells

    10 Aug 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210810005362/en

    BUSINESSWIRE
    10 Aug 2021
    Share Share
    Bristol Myers Empliciti (Elotuzumab) Receives Supplemental Approval in US
    Bristol Myers Empliciti (Elotuzumab) Receives Supplemental Approval in US

    31 Oct 2019

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761035

    FDA
    31 Oct 2019
    Share Share
    Empliciti combo bags EU approval for multiple myeloma
    Empliciti combo bags EU approval for multiple myeloma

    29 Aug 2019

    // Anna Smith PHARMA TIMES

    http://www.pharmatimes.com/news/empliciti_combo_bags_eu_approval_for_multiple_myeloma_1299819

    Anna Smith PHARMA TIMES
    29 Aug 2019
    Share Share
    Bristol-Myers, AbbVie's multiple myeloma drug wins second EU nod as part of triple regimen
    Bristol-Myers, AbbVie's multiple myeloma drug wins second EU nod as part of triple regimen

    29 Aug 2019

    // Natalie Grover ENDPTS

    https://endpts.com/bristol-myers-abbvies-multiple-myeloma-drug-wins-second-eu-nod-as-part-of-triple-regimen/

    Natalie Grover ENDPTS
    29 Aug 2019
    Share Share
    EC OKs expanded label for Bristol-Myers' Empliciti
    EC OKs expanded label for Bristol-Myers' Empliciti

    27 Aug 2019

    // Douglas W. House SEEKINGALPHA

    https://seekingalpha.com/news/3495058-ec-oks-expanded-label-bristol-myers-empliciti

    Douglas W. House SEEKINGALPHA
    27 Aug 2019
    Share Share